Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Published:2016-09-22 Issue:12 Volume:128 Page:1562-1566
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chen Robert¹,Gopal Ajay K.²,Smith Scott E.³,Ansell Stephen M.⁴,Rosenblatt Joseph D.⁵,Savage Kerry J.⁶,Connors Joseph M.⁶,Engert Andreas⁷,Larsen Emily K.⁸,Huebner Dirk⁹,Fong Abraham⁸,Younes Anas¹⁰

Affiliation:

1. City of Hope National Medical Center, Duarte, CA;

2. Division of Medical Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA;

3. Division of Hematology and Medical Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL;

4. Mayo Clinic, Rochester, MN;

5. Division of Hematology and Oncology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL;

6. British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada;

7. German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany;

8. Seattle Genetics, Inc., Bothell, WA;

9. Millenium Pharmaceuticals, Inc., Cambridge, MA; and

10. Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Key Points A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/12/1562/1395621/1562.pdf

Reference18 articles.

1. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.;Sutherland;J Biol Chem,2006

2. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.;Oflazoglu;Blood,2007

3. Phase II investigator-initiated study of brentuximab vedotin in Mycosis Fungoides and Sezary Syndrome with variable CD30 expression level: A multi-institution collaborative project.;Kim;J Clin Oncol,2015

4. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.;Müller;Cancer Immunol Res,2014

5. Brentuximab vedotin-mediated immunogenic cell death [abstract].;Gardai;Cancer Res,2015

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study;Current Oncology;2024-07-04

3. Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data;Hitit Medical Journal;2024-06-30

4. What is the best salvage therapy for Hodgkin lymphoma?;Current Opinion in Oncology;2024-06-20

5. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease;American Society of Clinical Oncology Educational Book;2024-06